NCT02360774View on ClinicalTrials.gov

Mechanisms of Weight Loss With SGLT2 Inhibition

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Type 2 DiabetesOverweightObesity
Interventions
DRUG

Canagliflozin

Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.

DRUG

Placebo

Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT02360774 - Mechanisms of Weight Loss With SGLT2 Inhibition | Biotech Hunter | Biotech Hunter